Within 2 randomized , double-masked , phase 3 clinical trials ( RIDE [ A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema { ME } With Center Involvement Secondary to Diabetes Mellitus ; NCT00473382 ] and RISE [ A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema { ME } With Center Involvement Secondary to Diabetes Mellitus ; NCT00473330 ] ) , the NEI VFQ-25 was administered at baseline and at the 6 - , 12 - , 18 - , and 24-month follow-up visits .